Trials / Completed
CompletedNCT05567510
A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants
A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of [14C] BMS-986369 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess mass balance, biotransformation, and excretion of BMS-986369 following study drug administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986369 | Specified dose on specified days |
Timeline
- Start date
- 2022-10-20
- Primary completion
- 2022-12-27
- Completion
- 2022-12-27
- First posted
- 2022-10-05
- Last updated
- 2023-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05567510. Inclusion in this directory is not an endorsement.